David Pérez-Callejo

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser et al. · New England Journal of Medicine · 2022 · 676 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 413 citations · Full text

Life Sciences, Immunology, Oncology +17

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

Julia González‐Rincón, Míriam Méndez, Sagrario Gómez et al. · PLoS ONE · 2019 · 53 citations · Full text

Medicine, Genetics, Molecular Genetics +17

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study

Susanna Hegewisch-Becker, Guillermo Méndez, Joseph Chao et al. · Journal of Clinical Oncology · 2024 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma

Lucía Pedrosa, Ismael Fernández‐Miranda, David Pérez-Callejo et al. · Scientific Reports · 2021 · 45 citations · Full text

Medicine, Genetics, Hematology +16